Addex Therapeutics announced that its collaboration agreement with Indivior PLC for discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates has been extended until March 31, 2023. As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx. USD 900,000) of additional research funding.

The reserved indications, where Addex retains exclusive rights to develop its own independent GABAB PAM program, have also been expanded to include chronic cough, in addition to the rights to develop certain retained compounds for Charcot-Marie-Tooth type 1A neuropathy (CMT1A) and pain. Indivior continues to be an important strategic partner for Addex as continues to advance preclinical portfolio towards the clinic and await the readout from the ADX71149 Phase 2 epilepsy study being conducted by partner, Janssen Pharmaceuticals Inc., which is due to report top line data at the end of 2022.